Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells

MARIANELA CANDOLFI; JAMES F CURTIN; WEIDONG XIONG; KURT M KROEGER; CHUNYAN LIU; ALTAN RENTSENDORJ; HASMIK AGDJANIAN; LALI MEDINA-KAUWE; DONNA PALMER; PHILLIP NG; PEDRO R LOWENSTEIN; MARIA G CASTRO

MOLECULAR THERAPY (PRINT)

NATURE PUBLISHING GROUP

Año: 2006 p. 371 - 381

1525-0016

Glioblastoma multiforme (GBM) is the most common subtype of primary malignant brain tumor. Although serotype 5 adenoviral vectors (Ads) have been used successfully in clinical trials for GBM, the capacity of Ads to infect human glioma cells and the expression of adenoviral receptors in GBM cells have been challenged. In this report, we studied the expression of three molecules that have been shown to mediate adenoviral entry into cells, i.e., coxsackie and adenovirus receptor (CAR), integrin alphavbeta3 (INT), and major histocompatibility complex class I (MHCI), in rodent glioma cell lines and low-passage primary cultures and cell lines from human GBM. We correlated levels of expression of CAR, INT, and MHCI with transduction efficiency elicited by several high-capacity helper-dependent adenoviral vectors (HC-Ads). Expression levels of adenoviral receptors were variable among the different GBM cells studied. HC-Ad-mediated therapeutic gene expression was efficient, ranging between 20 and 80% of the total target cells expressing the encoded transgenes. Our results show no correlation between the levels of CAR, INT, or MHCI molecules and the levels of transgene expression or the number of GBM cells transduced. We conclude that expression levels of adenoviral receptors do not predict their transduction efficiency or biological function.